CS Group (OTCQB: CSDX) announced on February 11, 2026, the appointment of Shah Teelani & Associates, a Dubai-based PCAOB-registered auditor, to oversee the consolidation and audit of its 2025 financial statements. The engagement covers CS Diagnostics Corp. (OTCQB: CSDX), CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH, reflecting the Group's commitment to strengthening financial governance, regulatory compliance, and transparency.
The appointment marks a significant step in aligning the Group's financial reporting structure with U.S. public company standards while integrating its growing international operations under a unified reporting framework. The consolidated audit is expected to enhance financial clarity, streamline reporting processes, and bolster investor confidence as the Group advances its international expansion strategy across the United States, GCC region, and Europe.
The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. Management emphasized that engaging a PCAOB-registered audit firm is crucial for maintaining institutional-grade standards as the company scales globally.
Mohammad Essayed, Group Chief Financial Officer, stated: "Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group's evolution as a publicly traded company. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy."
CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform in infection control and oncology. Its portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations, and CS Protect-Hydrogel, a tissue spacer for prostate cancer radiotherapy. The company is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap.
For further information, please visit https://group-csd.com/.
